GLP-1 Resource Hub
Posted on August 5, 2024
Resources to Support Payers’ GLP-1 Strategies
GLP-1s are a class of medications that can help manage type 2 diabetes and obesity. In recent years, their use has grown substantially due to their expanded indications (most recently for cardiovascular disease) and growing exposure in the mainstream media surrounding their effectiveness for weight loss. However, these therapies costs about $12,000 per member per year before rebates, prompting coverage discussions for the payers that cover them.
PSG has a wealth of GLP-1 resources produced by our clinical, research, and industry experts focused on education and actionable considerations for payers regarding their GLP-1 strategies. View our resources below!
The 2025 Payer’s Guide to GLP-1 Drugs
Download this guide, which shares the latest on the GLP-1 drug landscape and how payers can address the evolving clinical and financial impacts.
GLP-1 Coverage for Obesity and Weight Management Vendor Considerations
Download the issue brief to learn how organizations are viewing GLP-1 coverage for obesity, what to look for in a weight management point solution vendor, and more.
A GLP-1 Drugs Infographic
Download the infographic to see key report statistics about how organizations are viewing GLP-1 coverage for obesity and more.
Medication Shortages Impact Patients and Payers
The increasing popularity of FDA-approved GLP-1 medications has caused supply chain disruptions for patients with type 2 diabetes and those seeking obesity treatment.
GLP-1 Drugs Whitepaper: Understanding the Complexities of Coverage for Diabetes and Obesity
This white paper aims to assist plans in comprehending the subtle nuances and implications surrounding GLP-1s.
A Clinical Playbook Driven By Integrated Data
View the GLP-1 section of this Clinical Playbook to learn more about how plan sponsors can address GLP-1 management strategies.
GLP-1 Spotlight: Navigating Coverage, Costs, and Clinical Outcomes
Drawing from 2025 payer perspective data, this webinar presents the latest on GLP-1 coverage trends, affordability concerns, and innovative cost containment strategies.
Exploring Diabetes Management with GLP-1s
GLP-1s are still important for diabetes management, yet they are just one part of 7 other key considerations.
CMS Issues Coverage Guidance on GLP-1 Anti-Obesity Drugs: Implications for Health Plans
Read PSG’s expert analysis of the latest coverage guidance released by CMS and what it might mean for health plans.